TY - JOUR
T1 - The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood
AU - Fauroux, Brigitte
AU - Simões, Eric A F
AU - Checchia, Paul A
AU - Paes, Bosco
AU - Figueras-Aloy, Josep
AU - Manzoni, Paolo
AU - Bont, Louis
AU - Carbonell-Estrany, Xavier
N1 - Funding Information:
Sponsorship and article processing charges for this study were funded by AbbVie. Joanne Smith, Julie Blake (Reviewers 1 and 2) and Barry Rodgers-Gray (Reviewer 3), from Strategen Limited, undertook the systematic review following the protocol approved by the authors. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Editorial assistance in the preparation of this manuscript was provided by Julie Blake and Barry Rodgers-Gray. Support for this assistance was funded by AbbVie. The institute of Louis Bont received money for investigator initiated studies by MeMed, AstraZeneca, AbbVie, and Janssen. The institute of Louis Bont received money for consultancy by AstraZeneca, AbbVie, MedImmune, Janssen, Gilead and Novavax. Paul Checchia has acted as an expert advisor and speaker for AbbVie and has received honoraria in this regard. He has also received research grant funding from AstraZeneca. Brigitte Fauroux has received compensation as a neonatology board member from AbbVie. Josep Figueras-Aloy has acted as an expert advisor and speaker for AbbVie and has received honoraria in this regard. Paolo Manzoni has acted as a speaker for AbbVie, and as an expert advisor for AbbVie, TEVA, Medimmune, AstraZeneca, Janssen, and has received honoraria in this regard. Bosco Paes has received research funding from AbbVie Corporation and compensation as an advisor or lecturer from AbbVie and MedImmune. Eric Simões has received grant funding to his institution from Medimmune Inc., Glaxo Smith Kline Inc., and received consultancy fees to the institution, from AbbVie. Xavier Carbonell-Estrany has acted as an expert advisor and speaker for AbbVie and has received honoraria in this regard.
Publisher Copyright:
© 2017, The Author(s).
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Introduction: The REGAL (RSV Evidence—a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. The objective of this fifth publication was to determine the long-term respiratory morbidity associated with RSV lower respiratory tract infection (RSV LRTI) in early life. Methods: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. This was supplemented by inclusion of papers published whilst drafting the manuscript. Studies reporting data on the incidence and long-term wheezing and asthma following RSV LRTI in early life were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results: A total of 2337 studies were identified of which 74 were included. Prospective, epidemiologic studies consistently demonstrated that RSV LRTI is a significant risk factor for on-going respiratory morbidity characterized by transient early wheezing and recurrent wheezing and asthma within the first decade of life and possibly into adolescence and adulthood (high SOE). RSV LRTI was also associated with impaired lung function in these children (high SOE). Respiratory morbidity has been shown to result in reduced quality of life and increased healthcare resource use (moderate SOE). The mechanisms through which RSV contributes to wheezing/asthma development are not fully understood, but appear to relate to the viral injury, preexisting abnormal lung function and/or other factors that predispose to wheezing/asthma, including genetic susceptibility, altered immunology, eosinophilia, and associated risk factors such as exposure to environmental tobacco smoke (high SOE). Conclusion: There is growing evidence that RSV LRTI in early childhood is associated with long-term wheezing and asthma and impaired lung function. Future research should aim to fully elucidate the pathophysiological mechanisms through which RSV causes recurrent wheezing/asthma.
AB - Introduction: The REGAL (RSV Evidence—a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. The objective of this fifth publication was to determine the long-term respiratory morbidity associated with RSV lower respiratory tract infection (RSV LRTI) in early life. Methods: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. This was supplemented by inclusion of papers published whilst drafting the manuscript. Studies reporting data on the incidence and long-term wheezing and asthma following RSV LRTI in early life were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results: A total of 2337 studies were identified of which 74 were included. Prospective, epidemiologic studies consistently demonstrated that RSV LRTI is a significant risk factor for on-going respiratory morbidity characterized by transient early wheezing and recurrent wheezing and asthma within the first decade of life and possibly into adolescence and adulthood (high SOE). RSV LRTI was also associated with impaired lung function in these children (high SOE). Respiratory morbidity has been shown to result in reduced quality of life and increased healthcare resource use (moderate SOE). The mechanisms through which RSV contributes to wheezing/asthma development are not fully understood, but appear to relate to the viral injury, preexisting abnormal lung function and/or other factors that predispose to wheezing/asthma, including genetic susceptibility, altered immunology, eosinophilia, and associated risk factors such as exposure to environmental tobacco smoke (high SOE). Conclusion: There is growing evidence that RSV LRTI in early childhood is associated with long-term wheezing and asthma and impaired lung function. Future research should aim to fully elucidate the pathophysiological mechanisms through which RSV causes recurrent wheezing/asthma.
KW - Asthma
KW - Bronchial hyperreactivity
KW - Bronchiolitis
KW - Lower respiratory tract infection
KW - Lung function
KW - Recurrent wheezing
KW - Respiratory morbidity
KW - Sensitization
KW - Wheezing
UR - http://www.scopus.com/inward/record.url?scp=85020018702&partnerID=8YFLogxK
U2 - 10.1007/s40121-017-0151-4
DO - 10.1007/s40121-017-0151-4
M3 - Review article
C2 - 28357706
AN - SCOPUS:85020018702
SN - 2193-8229
VL - 6
SP - 173
EP - 197
JO - Infectious Diseases and Therapy
JF - Infectious Diseases and Therapy
IS - 2
ER -